See the DrugPatentWatch profile for Amvuttra
Amvuttra, the brand name for the drug tiragolumab, received its initial approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) on March 23, 2023 [1]. This approval was for the treatment of unresectable, recurrent, or metastatic non-small cell lung cancer (NSCLC) [1].
What is Amvuttra (tiragolumab) used for?
Amvuttra is an immune checkpoint inhibitor designed to target the TIGIT protein [1]. In NSCLC, it is administered in combination with atezolizumab (Tecentriq), another immunotherapy drug [1]. This combination aims to enhance the body's immune response against cancer cells.
What is the difference between tiragolumab and atezolizumab?
Tiragolumab is a novel anti-TIGIT antibody, while atezolizumab is an anti-PD-L1 antibody [1]. TIGIT and PD-L1 are both immune checkpoint proteins that can suppress the immune system's ability to fight cancer [1]. By blocking both TIGIT and PD-L1 pathways, the combination therapy aims to provide a more robust anti-tumor immune response than targeting either pathway alone [1].
When does tiragolumab patent expire?
Information regarding the specific patent expiration dates for tiragolumab is not readily available in the provided context. Patent information for pharmaceuticals is complex and can involve multiple patents covering composition of matter, manufacturing processes, and methods of use, each with its own expiration timeline. For detailed patent status, resources like DrugPatentWatch.com [2] would be necessary.
Are there other drugs like Amvuttra?
Yes, there are other immune checkpoint inhibitors approved for NSCLC, primarily targeting the PD-1/PD-L1 pathway. These include drugs such as pembrolizumab (Keytruda) and nivolumab (Opdivo). However, tiragolumab's novel mechanism of action targeting TIGIT differentiates it from existing PD-1/PD-L1 inhibitors and represents a new approach in cancer immunotherapy [1].
What are the clinical trial results for Amvuttra?
The approval in Japan was based on data from the Phase II CITYSCAPE study, which evaluated tiragolumab in combination with atezolizumab compared to atezolizumab alone in patients with PD-L1-positive, unresectable, locally advanced or metastatic NSCLC [1]. The study showed a statistically significant improvement in progression-free survival (PFS) and objective response rate (ORR) for the combination therapy versus atezolizumab monotherapy [1].
What are the next steps for Amvuttra's approval?
Following its approval in Japan, tiragolumab is under investigation in ongoing global clinical trials, including Phase III studies [1]. Further regulatory submissions in other regions are anticipated.
Sources:
[1] https://www.gene.com/media/press-releases/14938/roche-announces-tiragolumab-receives-first-approval-in-japan
[2] https://drugpatentwatch.com/